Biohaven Pharmaceutical (NYSE:BHVN) PT Lowered to $90.00

Biohaven Pharmaceutical (NYSE:BHVN) had its target price decreased by Mizuho from $98.00 to $90.00 in a research report report published on Tuesday morning, The Fly reports. Mizuho currently has a buy rating on the stock.

Several other equities analysts have also commented on the company. William Blair reissued a buy rating on shares of Biohaven Pharmaceutical in a research report on Friday, February 5th. Canaccord Genuity lowered their price objective on Biohaven Pharmaceutical from $110.00 to $101.00 and set a buy rating for the company in a research report on Tuesday, January 19th. Piper Sandler lifted their price target on Biohaven Pharmaceutical from $90.00 to $110.00 and gave the stock an overweight rating in a research report on Monday, March 1st. HC Wainwright lowered their price target on Biohaven Pharmaceutical from $121.00 to $111.00 and set a buy rating for the company in a research report on Tuesday, January 19th. Finally, Zacks Investment Research lowered Biohaven Pharmaceutical from a hold rating to a sell rating and set a $90.00 price target for the company. in a research report on Wednesday, February 3rd. One research analyst has rated the stock with a sell rating, one has given a hold rating and ten have issued a buy rating to the company. The company currently has a consensus rating of Buy and a consensus price target of $98.64.

Shares of BHVN stock opened at $69.85 on Tuesday. The stock has a fifty day moving average of $71.26 and a 200 day moving average of $81.69. Biohaven Pharmaceutical has a 52 week low of $43.83 and a 52 week high of $100.77. The firm has a market capitalization of $4.55 billion, a price-to-earnings ratio of -5.69 and a beta of 1.09.

Biohaven Pharmaceutical (NYSE:BHVN) last announced its quarterly earnings results on Sunday, May 9th. The company reported ($4.21) EPS for the quarter, missing analysts’ consensus estimates of ($2.92) by ($1.29). The company had revenue of $43.82 million during the quarter, compared to the consensus estimate of $36.46 million. During the same period last year, the firm earned ($2.39) earnings per share. The firm’s revenue for the quarter was up 3710.4% compared to the same quarter last year. As a group, research analysts predict that Biohaven Pharmaceutical will post -12.38 EPS for the current year.

In other Biohaven Pharmaceutical news, Director John W. Childs purchased 13,157 shares of the firm’s stock in a transaction on Wednesday, March 17th. The stock was bought at an average cost of $76.00 per share, for a total transaction of $999,932.00. Also, Director John W. Childs purchased 10,000 shares of the firm’s stock in a transaction on Tuesday, March 2nd. The stock was acquired at an average price of $85.14 per share, with a total value of $851,400.00. Following the completion of the purchase, the director now owns 2,532,644 shares of the company’s stock, valued at approximately $215,629,310.16. The disclosure for this purchase can be found here. Insiders own 19.10% of the company’s stock.

Large investors have recently made changes to their positions in the company. US Bancorp DE purchased a new position in shares of Biohaven Pharmaceutical in the fourth quarter worth about $25,000. Valeo Financial Advisors LLC grew its holdings in Biohaven Pharmaceutical by 195.0% during the fourth quarter. Valeo Financial Advisors LLC now owns 295 shares of the company’s stock worth $25,000 after acquiring an additional 195 shares during the period. Farmers & Merchants Investments Inc. acquired a new stake in Biohaven Pharmaceutical during the fourth quarter worth about $26,000. Canada Pension Plan Investment Board grew its holdings in Biohaven Pharmaceutical by 120.0% during the fourth quarter. Canada Pension Plan Investment Board now owns 363 shares of the company’s stock worth $31,000 after acquiring an additional 198 shares during the period. Finally, Lazard Asset Management LLC acquired a new stake in Biohaven Pharmaceutical in the fourth quarter valued at approximately $53,000. Hedge funds and other institutional investors own 99.37% of the company’s stock.

Biohaven Pharmaceutical Company Profile

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological diseases and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as id developing Rimegepant for preventive treatment of migraine and other non-migraine indications; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications.

See Also: What is an investor looking for in an SEC filing?

The Fly

Analyst Recommendations for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.